CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
S1505 SWOG A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma Adult CIRB - Late Phase Emphasis
S1507 SWOG A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies Adult CIRB - Late Phase Emphasis
S1512 SWOG A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) Adult CIRB - Late Phase Emphasis
S1513 SWOG Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer Adult CIRB - Late Phase Emphasis
S1600 SWOG A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes Cancer Prevention and Control CIRB
S1602 SWOG A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Nave High-Grade Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis
S1605 SWOG Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis
S1607 SWOG A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy Adult CIRB - Late Phase Emphasis
S1608 SWOG Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Adult CIRB - Late Phase Emphasis
S1609 SWOG DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Adult CIRB - Late Phase Emphasis